These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 10087729)

  • 1. Hormonal ablation therapy for metastatic prostatic carcinoma: a review.
    Leewansangtong S; Soontrapa S
    J Med Assoc Thai; 1999 Feb; 82(2):192-205. PubMed ID: 10087729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H; Kanetake H
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen deprivation therapy for prostate cancer: current status and future prospects.
    Miyamoto H; Messing EM; Chang C
    Prostate; 2004 Dec; 61(4):332-53. PubMed ID: 15389811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Maximal androgen blockade in metastatic prostatic carcinoma].
    Jørgensen T; Tveter KJ
    Tidsskr Nor Laegeforen; 1997 Jan; 117(3):381-3. PubMed ID: 9064862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen.
    Beekman K; Morris M; Slovin S; Heller G; Wilton A; Bianco F; Scardino PT; Scher HI
    Urology; 2005 May; 65(5):947-52. PubMed ID: 15882729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal therapy for locally advanced prostate cancer.
    Einstein AB
    NCI Monogr; 1988; (7):171-4. PubMed ID: 3050536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hormone therapy for prostate cancer].
    Théodore C
    Bull Cancer; 2004 Jan; 91(1):69-74. PubMed ID: 14975807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of advanced prostate cancer: can we improve on androgen deprivation therapy?
    Anderson J; Abrahamsson PA; Crawford D; Miller K; Tombal B
    BJU Int; 2008 Jun; 101(12):1497-501. PubMed ID: 18336613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival benefit for early hormone ablation in biochemically recurrent prostate cancer.
    Tenenholz TC; Shields C; Ramesh VR; Tercilla O; Hagan MP
    Urol Oncol; 2007; 25(2):101-9. PubMed ID: 17349523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Usefulness and positioning of MAB therapy for prostate cancer].
    Akaza H; Chodak GW; Hirao Y
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1507-20. PubMed ID: 16227758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete androgen blockade for prostate cancer: what went wrong?
    Laufer M; Denmeade SR; Sinibaldi VJ; Carducci MA; Eisenberger MA
    J Urol; 2000 Jul; 164(1):3-9. PubMed ID: 10840412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of current status of total androgen deprivation in metastasized prostate cancer.
    Debruyne FM; Witjes WP
    Eur Urol; 1993; 24 Suppl 2():67-71. PubMed ID: 8262129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologic basis of endocrine therapy for prostatic cancer.
    McConnell JD
    Urol Clin North Am; 1991 Feb; 18(1):1-13. PubMed ID: 1899494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Possibilities in drug therapy in prostatic carcinoma].
    Schmid HP
    Ther Umsch; 1995 Jun; 52(6):418-22. PubMed ID: 7541571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.
    Penson DF; Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M
    J Urol; 2005 Aug; 174(2):547-52; discussion 552. PubMed ID: 16006889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced prostatic carcinoma. Early versus late endocrine therapy.
    Kozlowski JM; Ellis WJ; Grayhack JT
    Urol Clin North Am; 1991 Feb; 18(1):15-24. PubMed ID: 1992569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.